journal article·2025-12-31Open access

In vivo toxicity of chitosan-based nanoparticles: a systematic review

Shela Salsabila, Miski Aghnia Khairinisa, Nasrul Wathoni, Irna Sufiawati, Wan Ezumi Mohd Fuad, Nur Kusaira Khairul Ikram, Muchtaridi Muchtaridi

Abstract

Chitosan nanoparticles have been extensively utilised as polymeric drug carriers in nanoparticles formulations due to their potential to enhance drug delivery, efficacy, and safety. Numerous toxicity studies have been previously conducted to assess the safety profile of chitosan-based nanoparticles. These toxicity studies employed various methodologies, including test animals, interventions, and different routes of administration. This review aims to summarise research on the safety profile of chitosan-based nanoparticles in drug delivery, with a focus on general toxicity tests to determine LD50 and NOAEL values. It can serve as a repository and reference for chitosan-based nanoparticles, facilitating future research and further development of drugs delivery system using chitosan nanoparticles. Publications from 2014 to 2024 were obtained from PubMed, Scopus, Google Scholar, and ScienceDirect, in accordance with the inclusion and exclusion criteria.The ARRIVE 2.0 guidelines were employed to evaluate the quality and risk-of-bias in the in vivo toxicity studies. The results demonstrated favourable toxicity profiles, often exhibiting reduced toxicity compared to free drugs or substances. Acute toxicity studies consistently reported high LD50 values, frequently exceeding 5000 mg/kg body weight, while subacute studies typically revealed no significant adverse effects. Various routes of administration varied, including oral, intravenous, intraperitoneal, inhalation, and topical, each demonstrating promising safety profiles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University

Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Padjadjaran University

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran

Department of Oral Medicine, Faculty of Dentistry, Universitas Padjadjaran

Programme of Biomedicine, School of Health Sciences, USM Health Campus

Institute of Biological Sciences, Faculty of Science, Universiti Malaya

Funding

Indonesia Endowment Fund for Education · Research Applied Grants of The Ministry of Education, Culture, Research, and Technology Indonesia

References (100+)

Show source-provided references
1. 10.3390/polym1507159610.3390/polym15071596 ↗
2. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
3. 10.1016/j.yexmp.2008.12.00410.1016/j.yexmp.2008.12.004 ↗
4. 10.3390/nano1204061810.3390/nano12040618 ↗
5. 10.1016/j.mtchem.2023.10140010.1016/j.mtchem.2023.101400 ↗
6. 10.1016/j.aca.2019.04.03210.1016/j.aca.2019.04.032 ↗
7. 10.1002/mco2.32710.1002/mco2.327 ↗
8. 10.1186/s43094-022-00400-010.1186/s43094-022-00400-0 ↗
9. 10.1615/critrevtherdrugcarriersyst.v19.i2.1010.1615/critrevtherdrugcarriersyst.v19.i2.10 ↗
10. 10.1007/s11095-006-9132-010.1007/s11095-006-9132-0 ↗
11. 10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗
12. 10.3109/0363904980910857110.3109/03639049809108571 ↗
13. 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-410.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
14. 10.1007/978-3-030-50703-9_710.1007/978-3-030-50703-9_7 ↗
15. 10.1016/j.xphs.2020.05.00110.1016/j.xphs.2020.05.001 ↗
16. 10.3390/pharmaceutics1408167010.3390/pharmaceutics14081670 ↗
17. 10.1021/nl801736q10.1021/nl801736q ↗
18. 10.1021/acs.chemrev.5b0034610.1021/acs.chemrev.5b00346 ↗
19. 10.1016/j.ijpharm.2017.10.00510.1016/j.ijpharm.2017.10.005 ↗
20. 10.1007/s00210-022-02245-z10.1007/s00210-022-02245-z ↗
21. 10.3390/gels803017310.3390/gels8030173 ↗
22. 10.1021/acs.chemrev.3c0070510.1021/acs.chemrev.3c00705 ↗
23. 10.3390/polym303137710.3390/polym3031377 ↗
24. 10.4012/dmj.2017-15610.4012/dmj.2017-156 ↗
25. 10.3390/pharmaceutics1308129110.3390/pharmaceutics13081291 ↗
26. 10.3390/polym1319325610.3390/polym13193256 ↗
27. 10.1248/cpb.58.142310.1248/cpb.58.1423 ↗
28. 10.1016/j.heliyon.2021.e0867410.1016/j.heliyon.2021.e08674 ↗
29. 10.1016/j.ntm.2024.10004010.1016/j.ntm.2024.100040 ↗
30. 10.1016/j.jconrel.2022.10.00510.1016/j.jconrel.2022.10.005 ↗
31. 10.3390/pharmaceutics1608104310.3390/pharmaceutics16081043 ↗
32. 10.3390/pharmaceutics904005310.3390/pharmaceutics9040053 ↗
33. 10.15171/apb.2019.02310.15171/apb.2019.023 ↗
34. 10.1016/j.ajps.2017.04.00210.1016/j.ajps.2017.04.002 ↗
35. 10.21608/ajnsa.2018.2630.104010.21608/ajnsa.2018.2630.1040 ↗
36. 10.1016/j.carbpol.2021.11862310.1016/j.carbpol.2021.118623 ↗
37. 10.1111/cbdd.1281410.1111/cbdd.12814 ↗
38. 10.1016/j.ijbiomac.2023.12467310.1016/j.ijbiomac.2023.124673 ↗
39. 10.15171/apb.2019.04810.15171/apb.2019.048 ↗
40. 10.1016/j.sjbs.2022.02.01210.1016/j.sjbs.2022.02.012 ↗
41. 10.1351/PAC-CON-11-01-0610.1351/PAC-CON-11-01-06 ↗
42. 10.3390/polym1518365810.3390/polym15183658 ↗
43. 10.3390/molecules2602027210.3390/molecules26020272 ↗
44. 10.1016/j.bmt.2023.09.00110.1016/j.bmt.2023.09.001 ↗
45. 10.1371/journal.pbio.300041010.1371/journal.pbio.3000410 ↗
46. 10.1136/bmj.n7110.1136/bmj.n71 ↗
47. 10.3389/fbioe.2023.117715110.3389/fbioe.2023.1177151 ↗
48. 10.2147/dddt.S44749610.2147/dddt.S447496 ↗
49. 10.3390/pharmaceutics1312199310.3390/pharmaceutics13121993 ↗
50. 10.1016/j.jsps.2017.10.01210.1016/j.jsps.2017.10.012 ↗
51. 10.1155/2023/664010310.1155/2023/6640103 ↗
52. 10.1007/s11051-023-05690-w10.1007/s11051-023-05690-w ↗
53. OECD. Test No. 425: acute oral toxicity: up-and-down procedure; 2022.
54. OECD. Test No. 407: repeated dose 28-day oral toxicity study in rodents; 2008.
55. 10.1016/j.ejmech.2022.11499510.1016/j.ejmech.2022.114995 ↗
56. 10.3390/md1109351710.3390/md11093517 ↗
57. 10.1038/s41598-024-55900-110.1038/s41598-024-55900-1 ↗
58. 10.1080/10717544.2021.194439810.1080/10717544.2021.1944398 ↗
59. 10.3389/fonc.2022.85501910.3389/fonc.2022.855019 ↗
60. 10.1016/j.biopha.2018.07.02910.1016/j.biopha.2018.07.029 ↗
61. 10.1016/j.phrs.2015.07.02510.1016/j.phrs.2015.07.025 ↗
62. 10.2147/ijn.S29046610.2147/ijn.S290466 ↗
63. 10.1016/j.jsps.2019.11.01810.1016/j.jsps.2019.11.018 ↗
64. Clarke DA, Philips FS, Sternberg SS, et al. 6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. Cancer Res. 1953;13(8):593–604.
65. 10.2147/IJN.S2152310.2147/IJN.S21523 ↗
66. 10.3892/ol.2017.721010.3892/ol.2017.7210 ↗
67. RM Mosaad AS HM Ibrahim. Median lethal dose (LD50) and cytotoxicity of Adriamycin in female albino mice. J Appl Pharm Sci. 2017;7:077–080.
68. 10.1016/j.cej.2017.12.11010.1016/j.cej.2017.12.110 ↗
69. 10.1016/j.ejps.2018.08.03810.1016/j.ejps.2018.08.038 ↗
70. 10.1016/j.carbpol.2021.11823710.1016/j.carbpol.2021.118237 ↗
71. 10.2147/ijn.S23235010.2147/ijn.S232350 ↗
72. 10.1016/j.ejps.2019.10502610.1016/j.ejps.2019.105026 ↗
73. 10.1039/d2tb00856d10.1039/d2tb00856d ↗
74. 10.1016/j.ejpb.2022.01.00910.1016/j.ejpb.2022.01.009 ↗
75. 10.1016/j.jddst.2022.10371210.1016/j.jddst.2022.103712 ↗
76. 10.1089/jamp.2009.080610.1089/jamp.2009.0806 ↗
77. 10.1186/s12951-023-01824-310.1186/s12951-023-01824-3 ↗
78. 10.1007/s13204-015-0502-y10.1007/s13204-015-0502-y ↗
79. 10.1186/s13578-015-0041-y10.1186/s13578-015-0041-y ↗
80. 10.1016/j.lfs.2022.12050010.1016/j.lfs.2022.120500 ↗
81. 10.1049/iet-nbt.2018.511410.1049/iet-nbt.2018.5114 ↗
82. 10.1016/j.micpath.2016.02.00710.1016/j.micpath.2016.02.007 ↗
83. 10.1016/j.ijpharm.2020.11995810.1016/j.ijpharm.2020.119958 ↗
84. 10.1016/j.ijpharm.2013.01.02410.1016/j.ijpharm.2013.01.024 ↗
85. 10.1002/jps.2466610.1002/jps.24666 ↗
86. 10.1159/00048817110.1159/000488171 ↗
87. 10.1016/j.foodchem.2020.12719510.1016/j.foodchem.2020.127195 ↗
88. 10.1080/1091581070187626510.1080/10915810701876265 ↗
89. 10.1111/1750-3841.1225610.1111/1750-3841.12256 ↗
90. Shinde A. Lovastatin loaded chitosan nanoparticles: preparation, evaluation and in vitro release studies. Res J Pharm Technol J. 2011;4:1869–1876.
91. 10.1038/s41598-020-57666-810.1038/s41598-020-57666-8 ↗
92. 10.1007/s13239-018-0357-y10.1007/s13239-018-0357-y ↗
93. 10.1016/j.eurpolymj.2017.05.01510.1016/j.eurpolymj.2017.05.015 ↗
94. 10.1016/j.ijbiomac.2021.06.08510.1016/j.ijbiomac.2021.06.085 ↗
95. 10.1016/j.msec.2020.11144210.1016/j.msec.2020.111442 ↗
96. 10.1016/j.biopha.2018.07.10610.1016/j.biopha.2018.07.106 ↗
97. 10.3390/biomedicines1202028710.3390/biomedicines12020287 ↗
98. 10.1007/s00289-022-04599-z10.1007/s00289-022-04599-z ↗
99. 10.1016/j.ijpharm.2023.12288410.1016/j.ijpharm.2023.122884 ↗
100. 10.3390/pharmaceutics1201004310.3390/pharmaceutics12010043 ↗